Brian G. Oliver

Prof. Brian G. Oliver

University of Technology Sydney, Sydney, New South Wales, Australia
+1
orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
Emma BeckettEmma Beckett
Emma Beckett
RSRichard L. Stevens
Richard L. Stevens
AJAndrew G. Jarnicki
Andrew G. Jarnicki
RKRichard Y. Kim
Richard Y. Kim
IHIrwan Hanish
Irwan Hanish
PHPhilip M. Hansbro
Philip M. Hansbro

5 April 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MAMicheál Mac Aogáin
Micheál Mac Aogáin
JNJayanth Kumar Narayana
Jayanth Kumar Narayana
PTPei Yee Tiew
Pei Yee Tiew
NANur A’tikah Binte Mohamed Ali
Nur A’tikah Binte Mohamed Ali
VYValerie Fei Lee Yong
Valerie Fei Lee Yong
SCSanjay Haresh Chotirmall
Sanjay Haresh Chotirmall

20 August 2020 in Mucosal Immunology
Verified
Journal Article
Closed access
PDF file
MJM D Johansen
M D Johansen
AIA Irving
A Irving
XMX Montagutelli
X Montagutelli
MTM D Tate
M D Tate
IRI Rudloff
I Rudloff
PHPhilip M. Hansbro
Philip M. Hansbro

3 March 2012 in Thorax
Verified
Journal Article
Open access
PDF file
Ama-Tawiah EssilfieAma-Tawiah Essilfie
Ama-Tawiah Essilfie
JSJodie L Simpson
Jodie L Simpson
MDMargaret L Dunkley
Margaret L Dunkley
LMLucy Morgan
Lucy Morgan
Brian G. OliverBrian G. Oliver
Brian G. Oliver
PHPhilip M. Hansbro
Philip M. Hansbro
Background 20–30% of patients with asthma have neutrophilic airway inflammation and reduced responsiveness to steroid therapy. They often have chronic airway bacterial colonisation and Haemophilus influenzae is one of the most commonly isolated bacteria. The relationship between chronic airway colonisation and the development of steroid-resistant neutrophilic asthma is unclear. Objectives To investigate the relationship between H influenzae respiratory infection and neutrophilic asthma using mouse models of infection and ovalbumin (OVA)-induced allergic airways disease. Methods BALB/c mice were intratracheally infected with H influenzae (day 10), intraperitoneally sensitised (day 0) and intranasally challenged (day 12–15) with OVA. Treatment groups were administered dexamethasone intranasally during OVA challenge. Infection, allergic airways disease, steroid sensitivity and immune responses were assessed (days 11, 16 and 21). Results The combination of H influenzae infection and allergic airways disease resulted in chronic lung infection that was detected on days 11, 16 and 21 (21, 26 and 31 days after infection). Neutrophilic allergic airways disease and T helper 17 cell development were induced, which did not require active infection. Importantly, all features of neutrophilic allergic airways disease were steroid resistant. Toll-like receptor 4 expression and activation of phagocytes was reduced, but most significantly the influx and/or development of phagocytosing neutrophils and macrophages into the airways was inhibited. Conclusions The combination of infection and allergic airways disease promotes bacterial persistence, leading to the development of a phenotype similar to steroid-resistant neutrophilic asthma and which may result from dysfunction in innate immune cells. This indicates that targeting bacterial infection in steroid-resistant asthma may have therapeutic benefit.

22 July 2009 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
SSSacha Stelzer‐Braid
Sacha Stelzer‐Braid
Brian G. OliverBrian G. Oliver
Brian G. Oliver
ABAngus J. Blazey
Angus J. Blazey
EAElizabeth Argent
Elizabeth Argent
TNTimothy Newsome
Timothy Newsome
ETEuan R. Tovey
Euan R. Tovey

1 March 2018 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
Hui ChenHui Chen
Hui Chen
GLGerard Li
Gerard Li
YCYik Lung Chan
Yik Lung Chan
DCDavid G. Chapman
David G. Chapman
SSSuporn Sukjamnong
Suporn Sukjamnong
Brian G. OliverBrian G. Oliver
Brian G. Oliver
E-cigarette usage is increasing, especially among the young, with both the general population and physicians perceiving them as a safe alternative to tobacco smoking. Worryingly, e-cigarettes are commonly used by pregnant women. As nicotine is known to adversely affect children in utero, we hypothesized that nicotine delivered via e-cigarettes would negatively affect lung development. To test this, we developed a mouse model of maternal e-vapor (nicotine and nicotine-free) exposure and investigated the impact on the growth and lung inflammation in both offspring and mothers. Female Balb/c mice were exposed to e-fluid vapor containing nicotine (18 mg/ml nicotine E-cigarette [E-cig18], equivalent to two cigarettes per treatment, twice daily,) or nicotine free (E-cig0 mg/ml) from 6 weeks before mating until pups weaned. Male offspring were studied at Postnatal Day (P) 1, P20, and at 13 weeks. The mothers were studied when the pups weaned. In the mothers’ lungs, e-cigarette exposure with and without nicotine increased the proinflammatory cytokines IL-1β, IL-6, and TNF-α. In adult offspring, TNF-α protein levels were increased in both E-cig18 and E-cig0 groups, whereas IL-1β was suppressed. This was accompanied by global changes in DNA methylation. In this study, we found that e-cigarette exposure during pregnancy adversely affected maternal and offspring lung health. As this occurred with both nicotine-free and nicotine-containing e-vapor, the effects are likely due to by-products of vaporization rather than nicotine.